High throughput monitoring of safety, potency and stability of gene therapy cell products in lysosomal disease patients
Luca Biasco(ProterixBio (United States)), Chris Mason(Oak Ridge National Laboratory), Mariana Loperfido(ProterixBio (United States)), Ingrid Abrahamsen(ProterixBio (United States)), Azadeh Golipour(ProterixBio (United States)), Aimin Yan(ProterixBio (United States)), Cristina Baricordi(Broad Institute), Luigi Barbarossa(ProterixBio (United States))
Cited by 0
Related Papers
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
Highly efficient therapeutic gene editing of human hematopoietic stem cells
|Nature Medicine|2019|518
BTRFS
|ACM Transactions on Storage|2013|381
Lancet Commission: Stem cells and regenerative medicine
|The Lancet|2017|276
Cell Therapy Industry: Billion Dollar Global Business with Unlimited Potential
|Regenerative Medicine|2011|144